-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
16 Dec 2025 03:09 GMT
… trial, said: “Trastuzumab deruxtecan plus pertuzumab is the only 1st-line treatment … with foundational medicines fulvestrant and goserelin and … BIOTECHNOLOGY HEALTH WOMEN PHARMACEUTICAL ONCOLOGY OTHER SCIENCE RESEARCH GENETICS CONSUMER SCIENCE CLINICAL TRIALS …
-
<![CDATA[Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials]]>
20 Oct 2025 22:21 GMT
… FirstWord Pharma, some doctors have had reservations around … breast cancer medicine and consultant medical oncologist at The … NATALEE trial (NCT03701334) of Kisqali (ribociclib) revealed that treatment … or letrozole) with goserelin as indicated.
The primary …
-
Enhertu demonstrated highly statistically significant and clinically meaningful improvement in IDFS vs. T─DM1 in DESTINY─Breast05 phase III trial in patients with high─risk early breast cancer following neoadjuvant therapy
30 Sep 2025 05:35 GMT
… DESTINY-Breast05 phase III trial showed Enhertu (trastuzumab … HER2-directed DXd antibody drug conjugate (ADC) discovered … . Trials in combination with other anti-cancer treatments, … with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and …
-
Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
25 Sep 2025 03:31 GMT
… Drug Administration (FDA) grants Priority Review to applications for medicines … was stratified by prior treatment (de novo metastatic … 47;or DESTINY-Lung05 trials. Continued approval in … foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and …
-
Advances of Drug-Loaded Microsphere Technology for Targeted Immunotherapy Against Prostate Cancer
19 Sep 2025 16:43 GMT
… , Phase 2 Trial (the TRENDY Trial). Int J … received goserelin microsphere + ARV-766 microsphere embolization treatment, and … as collaboration across clinical medicine, data science, and … Drug Delivery Applications: An Overview of Recent Advances. Pharmaceutics. …
-
Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?
11 Sep 2025 19:58 GMT
… 2 gene test, and goserelin was given for ovarian … United States Food and Drug Administration (FDA) approved the application … her overall survival. Local treatment (radiofrequency ablation) may be … review of the literature. Medicine. 2020;99(42):e22665. …
-
Breast cancer drug ALERT: Seasoned medical writer Dr. Vernon Coleman CONDEMNS ZOLADEX saying itâs dangerous, ineffective and misused
18 Jul 2025 07:48 GMT
… research into pharmaceutical side effects, … trials involving 6,279 patients found that combining Zoladex (goserelin … treatment options and reject unnecessary, harmful medications.
Zoladex is a hormone therapy drug … natural remedies for preventative medicine and …
-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
01 Jun 2025 12:10 GMT
… free survival (PFS). The trial evaluated switching to the camizestrant … how we think about drug resistance in this type … in Phase III trials for the treatment of HR-positive … outcomes with foundational medicines fulvestrant and goserelin and aims to …
-
Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer
03 Jun 2025 12:31 GMT
… of recurrence and fewer treatment discontinuations due to adverse … anastrozole or letrozole) and goserelin if applicable. The primary … from China’s National Medical Products Administration. In MBC … across three phase III trials. The NCCN Guidelines also …
-
AstraZeneca & Daiichi Sankyo announce positive results from DESTINY-Breast09 phase III trial of Enhertu plus pertuzumab to treat HER2-positive metastatic breast cancer
03 Jun 2025 08:43 GMT
… DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab … was stratified by prior treatment (de novo metastatic disease … 47;or DESTINY-Gastric06 trials. Continued approval in … with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and …
About
© 1995-2025